Exagen (XGN) News Today $3.84 -0.40 (-9.43%) Closing price 04:00 PM EasternExtended Trading$3.86 +0.02 (+0.52%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Exagen Inc. (NASDAQ:XGN) Sees Significant Decline in Short InterestExagen Inc. (NASDAQ:XGN - Get Free Report) was the recipient of a large drop in short interest in February. As of February 28th, there was short interest totalling 23,000 shares, a drop of 29.2% from the February 13th total of 32,500 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average trading volume of 166,100 shares, the days-to-cover ratio is currently 0.1 days.March 16, 2025 | marketbeat.comCantor Fitzgerald Reduces Earnings Estimates for ExagenExagen Inc. (NASDAQ:XGN - Free Report) - Cantor Fitzgerald decreased their FY2025 earnings estimates for Exagen in a research note issued to investors on Wednesday, March 12th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will earn ($0.59) per share for the year, down fromMarch 15, 2025 | marketbeat.comWilliam Blair Forecasts Exagen's Q1 Earnings (NASDAQ:XGN)Exagen Inc. (NASDAQ:XGN - Free Report) - Investment analysts at William Blair lifted their Q1 2025 earnings per share estimates for Exagen in a report released on Wednesday, March 12th. William Blair analyst A. Brackmann now anticipates that the company will earn ($0.20) per share for the quarterMarch 15, 2025 | marketbeat.comExagen Inc. (NASDAQ:XGN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?March 14, 2025 | finance.yahoo.comWilliam Blair Predicts Exagen's FY2026 Earnings (NASDAQ:XGN)Exagen Inc. (NASDAQ:XGN - Free Report) - William Blair issued their FY2026 earnings estimates for Exagen in a note issued to investors on Wednesday, March 12th. William Blair analyst A. Brackmann anticipates that the company will post earnings of ($0.23) per share for the year. William Blair hasMarch 14, 2025 | marketbeat.comWilliam Blair Reiterates Outperform Rating for Exagen (NASDAQ:XGN)William Blair reaffirmed an "outperform" rating on shares of Exagen in a report on Wednesday.March 13, 2025 | marketbeat.comExagen Full Year 2024 Earnings: EPS Beats ExpectationsMarch 12, 2025 | uk.finance.yahoo.comExagen Inc. (NASDAQ:XGN) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | msn.comExagen (XGN) Gets a Buy from Canaccord GenuityMarch 12, 2025 | markets.businessinsider.comExagen Inc. Reports Record Revenue and Positive OutlookMarch 12, 2025 | tipranks.comExagen (NASDAQ:XGN) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPSExagen (NASDAQ:XGN - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.07. Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%.March 12, 2025 | marketbeat.comCantor Fitzgerald Forecasts Increased Earnings for ExagenExagen Inc. (NASDAQ:XGN - Free Report) - Stock analysts at Cantor Fitzgerald boosted their FY2024 EPS estimates for Exagen in a research note issued on Monday, March 10th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of ($0.84) for the year, upMarch 12, 2025 | marketbeat.comExagen reports Q4 EPS (20c), consensus (24c)March 12, 2025 | markets.businessinsider.comExagen Inc. Reports Record 2024 Financial ResultsMarch 12, 2025 | tipranks.comExagen Inc. (XGN) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | seekingalpha.comExagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business HighlightsMarch 11, 2025 | globenewswire.comExagen Inc. (NASDAQ:XGN) Short Interest UpdateExagen Inc. (NASDAQ:XGN - Get Free Report) was the target of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 32,500 shares, a growth of 21.7% from the January 31st total of 26,700 shares. Based on an average trading volume of 176,700 shares, the short-interest ratio is presently 0.2 days. Approximately 0.4% of the shares of the company are sold short.March 6, 2025 | marketbeat.comExagen (XGN) to Release Quarterly Earnings on TuesdayExagen (NASDAQ:XGN) will be releasing earnings before the market opens on Tuesday, March 11, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=292486)March 4, 2025 | marketbeat.comInvestors in Exagen (NASDAQ:XGN) have unfortunately lost 84% over the last five yearsMarch 2, 2025 | finance.yahoo.comExagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025February 25, 2025 | globenewswire.comExagen Inc. (NASDAQ:XGN) Short Interest Up 260.8% in JanuaryExagen Inc. (NASDAQ:XGN - Get Free Report) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 26,700 shares, a growth of 260.8% from the January 15th total of 7,400 shares. Based on an average daily volume of 170,600 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.3% of the company's stock are sold short.February 12, 2025 | marketbeat.comExagen Inc. to Participate in Upcoming Investor ConferencesFebruary 4, 2025 | globenewswire.comRevealed Tomorrow: The Stocks Poised for Big Gains in FebruaryFebruary 2, 2025 | msn.comExagen Inc. (NASDAQ:XGN) Short Interest Down 90.7% in JanuaryExagen Inc. (NASDAQ:XGN - Get Free Report) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 7,400 shares, a drop of 90.7% from the December 31st total of 79,200 shares. Based on an average daily volume of 140,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.1% of the shares of the company are sold short.January 30, 2025 | marketbeat.comFY2024 EPS Estimates for Exagen Lowered by Cantor FitzgeraldExagen Inc. (NASDAQ:XGN - Free Report) - Analysts at Cantor Fitzgerald reduced their FY2024 earnings estimates for shares of Exagen in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings peJanuary 23, 2025 | marketbeat.comExagen Gains 28%, Insider Trades Reap BenefitJanuary 20, 2025 | finance.yahoo.comExagen (NASDAQ:XGN) Given "Overweight" Rating at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and set a $8.00 price target on shares of Exagen in a report on Monday.January 13, 2025 | marketbeat.comExagen Gets Conditional Approval For New Lupus And RA Biomarker Assays In New YorkJanuary 13, 2025 | markets.businessinsider.comExagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis ...January 12, 2025 | gurufocus.comExagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis ...January 12, 2025 | gurufocus.comExagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial ResultsJanuary 12, 2025 | globenewswire.comExagen price target raised to $7 from $5 at CanaccordJanuary 4, 2025 | markets.businessinsider.comCanaccord Genuity Group Forecasts Strong Price Appreciation for Exagen (NASDAQ:XGN) StockCanaccord Genuity Group increased their target price on shares of Exagen from $5.00 to $7.00 and gave the stock a "buy" rating in a report on Friday.January 3, 2025 | marketbeat.comExagen Inc. (NASDAQ:XGN) Short Interest Up 36.5% in DecemberExagen Inc. (NASDAQ:XGN - Get Free Report) saw a significant growth in short interest in December. As of December 15th, there was short interest totalling 78,100 shares, a growth of 36.5% from the November 30th total of 57,200 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average daily volume of 82,200 shares, the short-interest ratio is currently 1.0 days.December 28, 2024 | marketbeat.comExagen (NASDAQ:XGN) Trading 1.4% Higher - Still a Buy?Exagen (NASDAQ:XGN) Stock Price Up 1.4% - Time to Buy?December 25, 2024 | marketbeat.comExagen achieves key milestone with 1M patient tested by AVISE CTDDecember 13, 2024 | markets.businessinsider.comExagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTDDecember 12, 2024 | globenewswire.comExagen Inc. (NASDAQ:XGN) Shares Sold by Wasatch Advisors LPWasatch Advisors LP lowered its stake in Exagen Inc. (NASDAQ:XGN - Free Report) by 35.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 490,205 shares of the company's stock after selling 272,054 shares during theDecember 2, 2024 | marketbeat.comInsider Selling: Exagen Inc. (NASDAQ:XGN) Major Shareholder Sells 200,000 Shares of StockNovember 28, 2024 | insidertrades.comJohn Aballi Buys 24,305 Shares of Exagen Inc. (NASDAQ:XGN) StockNovember 19, 2024 | insidertrades.comCantor Fitzgerald Increases Earnings Estimates for ExagenExagen Inc. (NASDAQ:XGN - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2024 earnings estimates for shares of Exagen in a research report issued to clients and investors on Wednesday, November 13th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company wilNovember 18, 2024 | marketbeat.comWhat is William Blair's Forecast for Exagen FY2024 Earnings?Exagen Inc. (NASDAQ:XGN - Free Report) - Equities researchers at William Blair boosted their FY2024 earnings per share (EPS) estimates for Exagen in a report issued on Wednesday, November 13th. William Blair analyst A. Brackmann now forecasts that the company will post earnings per share of ($0.8November 18, 2024 | marketbeat.comExagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ...November 14, 2024 | finance.yahoo.comExagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD PlatformNovember 14, 2024 | globenewswire.comQ3 2024 Exagen Inc Earnings CallNovember 13, 2024 | uk.finance.yahoo.comExagen’s Strategic Advancements and Market Potential Drive Buy Rating Amidst Upcoming ADVISE Test LaunchNovember 13, 2024 | markets.businessinsider.comExagen Inc. (NASDAQ:XGN) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | msn.comExagen (NASDAQ:XGN) Receives "Outperform" Rating from William BlairWilliam Blair restated an "outperform" rating on shares of Exagen in a research report on Wednesday.November 13, 2024 | marketbeat.comExagen Inc. Reports Third Quarter 2024 ResultsNovember 13, 2024 | markets.businessinsider.comExagen Inc. Reports Q3 2024 Financial ResultsNovember 13, 2024 | markets.businessinsider.com Remove Ads Get Exagen News Delivered to You Automatically Sign up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter. Email Address XGN Media Mentions By Week XGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XGN News Sentiment▼1.440.78▲Average Medical News Sentiment XGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XGN Articles This Week▼21▲XGN Articles Average Week Remove Ads Get Exagen News Delivered to You Automatically Sign up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VMD News DCGO News LFMD News AIRS News SERA News BDSX News QIPT News CORBF News EUDA News TOI News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XGN) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XGN Stock Free XGN Stock Alerts